Skip to main content
HEM Pharma Inc. logo

HEM Pharma Inc. — Investor Relations & Filings

Ticker · 376270 ISIN · KR7376270005 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2024-11-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 376270

About HEM Pharma Inc.

https://hempharma.bio/

HEM Pharma Inc. is a biotechnology company specializing in microbiome-based healthcare solutions. The company researches and develops Live Biotherapeutic Products (LBPs), health functional foods, and other bio-products derived from human-effective microbes. A core component of its R&D is the proprietary Pharmaceutical Meta-Analysis System (PMAS), a technology platform that simulates the human gut microbiome to screen for and analyze beneficial microorganisms. In addition to its product pipeline, HEM Pharma provides personalized healthcare services based on microbiome analysis and offers Contract Development and Manufacturing Organization (CDMO) services for next-generation biological materials.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the share ownership of major shareholders and special related parties of 'HEM Pharma' following its KOSDAQ listing. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-11-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Ji Yosep) of HEM Pharma. This type of filing is a standard regulatory requirement for insiders to disclose their shareholdings and changes therein. In the context of the provided categories, this falls under 'Director's Dealing' (DIRS), which covers reports of share transactions or ownership changes by company directors and executives.
2024-11-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings for a specific individual (Wilhelm Holzapfel) in relation to the company HEM Pharma. This type of filing is a standard regulatory requirement for insiders (directors/major shareholders) to disclose their holdings, which falls under the 'Director's Dealing' category.
2024-11-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their shareholdings and changes therein. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider trades and changes in ownership status by company directors and executives.
2024-11-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This type of filing is a standard regulatory disclosure for insider shareholdings, which falls under the 'Director's Dealing' category in the provided schema.
2024-11-08 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 1% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed by HEM Pharma with the Financial Supervisory Service (FSS) in South Korea. This document details the final results of a public offering, including subscription and allocation data, shareholding changes, and the use of proceeds. In the context of Korean regulatory filings (DART), this is a standard post-offering report that falls under the category of share issuance and capital changes.
2024-10-29 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.